Skip to main content
Journal cover image

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival

Publication ,  Conference
Richardson, PG; Kernan, NA; Grupp, SA; Martin, PL; Soiffer, RJ; Martin, R; Hannah, A; Villa, KF
Published in: Biology of Blood and Marrow Transplantation
February 2015

Duke Scholars

Published In

Biology of Blood and Marrow Transplantation

DOI

ISSN

1083-8791

Publication Date

February 2015

Volume

21

Issue

2

Start / End Page

S110 / S110

Publisher

Elsevier BV

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Richardson, P. G., Kernan, N. A., Grupp, S. A., Martin, P. L., Soiffer, R. J., Martin, R., … Villa, K. F. (2015). Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In Biology of Blood and Marrow Transplantation (Vol. 21, pp. S110–S110). Elsevier BV. https://doi.org/10.1016/j.bbmt.2014.11.138
Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Biology of Blood and Marrow Transplantation, 21:S110–S110. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.138.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, et al. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S110–S110.
Richardson, Paul G., et al. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” Biology of Blood and Marrow Transplantation, vol. 21, no. 2, Elsevier BV, 2015, pp. S110–S110. Crossref, doi:10.1016/j.bbmt.2014.11.138.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, Hannah A, Villa KF. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. Biology of Blood and Marrow Transplantation. Elsevier BV; 2015. p. S110–S110.
Journal cover image

Published In

Biology of Blood and Marrow Transplantation

DOI

ISSN

1083-8791

Publication Date

February 2015

Volume

21

Issue

2

Start / End Page

S110 / S110

Publisher

Elsevier BV

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences